Cell-resolved spatial mapping of antibody-drug conjugate targets in breast cancer
Translational Oncology · 2026-12 · 74 · 103068
DOI: 10.1016/j.tranon.2026.103068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Oncology, 2026-12. Verfasst von Yang Zhao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Program of Ningxia, National Natural Science Foundation of China, Natural Science Foundation of Ningxia Province.
Abstract (Originalsprache)
BACKGROUND: Antibody-drug conjugate (ADC) activity and target-dependent on-target/off-tumor toxicity depends in part on which cells express the target antigen, a feature that bulk assays cannot resolve. METHODS: We analyzed a publicly available whole-transcriptome CosMx breast tumor dataset including 154,816 cells and 18,934 genes. Eleven clinically relevant ADC targets were profiled across seven annotated lineages. Findings were contextualized using TCGA-BRCA bulk transcriptomes (1,097 tumors and 114 normal tissues) and assessed in two public Xenium breast cancer specimens. RESULTS: HER2 (ERBB2), TROP2 (TACSTD2), HER3 (ERBB3), NECTIN4 and MUC1 were enriched in tumor epithelium. B7-H3 (CD276) was highest in endothelial and myoepithelial cells, with similar mean expression in stromal and tumor cells. PSMA (FOLH1) was enriched in endothelium. TCGA-BRCA tumor-normal differences did not identify these cellular sources. No overall-survival association remained after multiple-testing correction or covariate adjustment. HER2 and TROP2 tumor enrichment recurred in both Xenium specimens, whereas EGFR was not tumor restricted. CONCLUSIONS: Cell-resolved spatial profiling separated ADC targets enriched in tumor epithelium from those expressed in vascular and stromal compartments. B7-H3 and PSMA localization was consistent with prior immunohistochemical reports and is confirmatory. These RNA-level results do not establish surface-protein abundance, ADC response, or clinical toxicity. Low-abundance microenvironmental findings remain based on a single discovery specimen and require protein-level validation. Protein-level confirmation, and correlation with ADC efficacy and toxicity, are required before these maps can inform clinical decisions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgical Oncology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
- Department of Anesthesiology and Perioperative Medicine, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.
- Department of Gastrointestinal Surgery, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia, China. Electronic address: litao2151@yeah.net.
Förderung
- Key Research and Development Program of Ningxia
- National Natural Science Foundation of China
- Natural Science Foundation of Ningxia Province
Zitieren
APA
Zhao, Y., Bai, Z., & Li, T. (2026). Cell-resolved spatial mapping of antibody-drug conjugate targets in breast cancer. Translational Oncology, 74, 103068. https://doi.org/10.1016/j.tranon.2026.103068
Vancouver
Zhao Y, Bai Z, Li T. Cell-resolved spatial mapping of antibody-drug conjugate targets in breast cancer. Translational Oncology. 2026;74:103068. doi:10.1016/j.tranon.2026.103068
BibTeX
@article{Zhao2026,
author = {Zhao, Yang and Bai, Zhixia and Li, Tao},
title = {Cell-resolved spatial mapping of antibody-drug conjugate targets in breast cancer},
journal = {Translational Oncology},
year = {2026},
volume = {74},
pages = {103068},
doi = {10.1016/j.tranon.2026.103068}
}
EUVIMED